Institutional members access full text with Ovid®

Share this article on:

Adjuvant Intraperitoneal Chemotherapy With Cisplatinum, Mitoxantrone, 5-Fluorouracil, and Calcium Folinate in Patients With Gastric Cancer: A Phase II Study

Topuz, Erkan M.D.; Basaran, Mert M.D.; Saip, Pnar M.D.ı; Aydiner, Adnan M.D.; Argon, Andac M.D.; Sakar, Burak M.D.; Tas, Faruk M.D.; Uygun, Kazim M.D.; Bugra, Dursun M.D.; Aykan, N. Faruk M.D.

American Journal of Clinical Oncology: December 2002 - Volume 25 - Issue 6 - p 619-624
Article

Gastric carcinoma remains one of the leading causes of cancer-related death in the world. Clinical studies have revealed that approximately two thirds of the patients seek treatment for early recurrence within the abdominal cavity. The aim of this phase II study was to evaluate the toxicity, feasibility, and efficacy of adjuvant intraperitoneal chemotherapy (IPCT) with cisplatin, mitoxantrone, 5-fluorouracil (5-FU), and folinic acid in patients with stage II-III gastric cancer. Patients with stage II and III gastric cancer aged between 15 and 70 years, after curative resection, with adequate liver, renal, and cardiac function were included in the study. The chemotherapy regimen consisted of cisplatin 60 mg/m2, mitoxantrone 12 mg/m2, 5-FU 600 mg/m2, and folinic acid 60 mg/m2, delivered intraperitoneally, diluted in 2 l normal saline. Intraperitoneal fluid was not drained. Each course of IPCT was repeated every 4 weeks for a total 6 cycles. Thirty-nine patients were enrolled in the study. Twenty-eight of the 39 patients (71.8%) completed six courses of the planned schedule. One patient (2.6%) died after a fourth cycle of IPCT from an undetermined reason. The major nonhematologic toxicity from IPCT was grade I-III nausea and/or vomiting experienced by 27 patients (69.2%). Twenty-four (61.5%) patients reported abdominal discomfort. Median follow-up was 23 (range: 3–105) months. Twenty-five patients (64.1%) were dead. Median disease-free survival and overall survival were 12 (CI 95%; 8.3–15.7 months) and 19 months (CI 95%; 10.5–27.5 months), respectively. The cumulative 5-year disease-free survival and overall survival were 24.7% and 30.7%, respectively. The regimen was generally associated with acceptable toxicity. However, adjuvant IPCT has similar survival rates in comparison to no adjuvant treatment; thus, it cannot be currently recommended outside the context of a clinical trial.

From the Medical Oncology Department, Institute of Oncology (E.T., M.B., P.S., Ad.A., An.A., B.S., F.T., K.U., N.F.A.), and General Surgery Department, Istanbul Medical Faculty (D.B.), Istanbul.

Address correspondence and reprint requests to Dr. Mert Basaran, Istasyon cad, Serra ap, 8/2, Yesilyurt, 34800, Istanbul, Turkey.

© 2002 Lippincott Williams & Wilkins, Inc.